The Effects and safety of ZincorespTM Tablets/ Syrup in Patients Having Ear, Nose, Throat and Respiratory Disorders and Infections.
- Conditions
- Health Condition 1: J00-J99- Diseases of the respiratory system
- Registration Number
- CTRI/2024/02/063092
- Lead Sponsor
- apex laboratories private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Age above 2 years of any gender.
2. Patients having recurrent episodes of any of the following:
- Fever associated with respiratory tract infections (RTI)
- URTI (rhinitis (Acute/allergic/Nonallergic), Common cold, Sinusitis, pharyngitis, laryngitis, influenza)
- SARS-CoV-2
- Combined allergic rhinitis and asthma syndrome (CARAS)
- Acute otitis media,
- titis media with effusion,
- Chronic suppurative otitis media
3. Patients and parents who are willing to give consent for their or the child’s participation respectively in study.
1. Any evidence of malignancy.
2. History and clinical findings suggestive of metabolic diseases
3. History and clinical findings suggest chronic respiratory tract diseases including interstitial lung disease (ILD) and cystic fibrosis.
4. History of respiratory tract surgery.
5. Known diagnosis of congenital cardiac defects.
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in symptoms of ear, nose, throat, and respiratory disorders and/or infectionsTimepoint: Baseline to Week 12
- Secondary Outcome Measures
Name Time Method